Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in Newly-diagnosed Glioblastoma and Recurrent Glioma
NCT05076513Phase 1Active, not recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib in glioblastoma (GBM) and glioma (2 arms), sponsored by Ivy Brain Tumor Center. Primary endpoints: Total and unbound niraparib concentration at Day 4, Presence of Chromosomal fusion at Day 4 and 1 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT05076513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076513.